SCHEMBL3583299

SCHEMBL3583299

Oc1nnc(O)c(-c2ccc(Cl)cc2)c1-c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.50
LMNA P02545 3/20 0.43
KDM4E B2RXH2 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LSS P48449 1/20 0.43
CYP19A1 P11511 2/20 0.42
MAPK14 Q16539 4/20 0.41
AKT1 P31749 3/20 0.41
MAPK13 O15264 2/20 0.41
MAPK12 P53778 2/20 0.41
MAPK11 Q15759 2/20 0.41
FLT3 P36888 1/20 0.41
GSK3B P49841 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 1/20 0.40
SRC P12931 1/20 0.40
BRAF P15056 1/20 0.40
KDR P35968 1/20 0.40
QDPR P09417 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4395903 0.94 GCGR (0.46) GCGRLMNAKDM4ERAB9ASMN1; SMN2
SCHEMBL3577494 0.89 ALOX5 (0.43) LMNAKDM4ERAB9ASMN1; SMN2MAPK1
SCHEMBL4391202 0.83 CASP1 (0.40) LMNAKDM4ERAB9ASMN1; SMN2MAPK1
SCHEMBL3558118 0.81 GCGR (0.55) GCGRLMNAKDM4ERAB9ASMN1; SMN2
SCHEMBL196861 0.78 GCGR (0.67) GCGRLMNAKDM4ERAB9ASMN1; SMN2
SCHEMBL3580926 0.73 NPC1 (0.39) KDM4ERAB9ASMN1; SMN2MAPK1GAA
SCHEMBL22137841 0.72 GCGR (0.59) GCGRLMNAKDM4ERAB9ASMN1; SMN2
SCHEMBL3574012 0.71 NPC1 (0.44) LMNAKDM4ERAB9ASMN1; SMN2MAPK1
SCHEMBL4390766 0.71 L3MBTL1 (0.49) LMNAKDM4ERAB9ASMN1; SMN2FLT3
SCHEMBL3555150 0.71 GCGR (0.58) GCGRLMNAKDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022526-A1 PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-01-28 US disclosed
EP-2121628-A1 PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES Syngenta Participations AG (CH) 2009-11-25 EP disclosed
WO-2008089934-A1 PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022526-A1 PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES CYP4Z1, CYP1A2, CYP1A1 GCGR 2362/4885LMNA 3036/4885KDM4E 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.